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Abstract
AIM
To examine treatment decisions of gastroenterologists 
regarding the choice of prescribing 5-aminosalycilates 
(5ASA) with corticosteroids (CS) versus corticosteroids 
alone for patients with active ulcerative colitis (UC). 
METHODS
A cross-sectional questionnaire exploring physicians’ 
attitude toward 5ASA + CS combination therapy vs  CS 
alone was developed and validated. The questionnaire 
was distributed to gastroenterology experts in twelve 
countries in five continents. Respondents’ agreement with 
stated treatment choices were assessed by standardized 
Likert scale. Background professional characteristics 
of respondents were analyzed for correlation with 
responses. 
RESULTS
Six hundred and sixty-four questionnaires were dis-
tributed and 349 received (52.6% response rate). Of 
340 eligible respondents, 221 (65%) would continue 
5ASA in a patient hospitalized for intravenous CS 
treatment due to a moderate-severe UC flare, while 108 
(32%) would stop the 5ASA (P  < 0.001), and 11 (3%) 
are undecided. Similarly, 62% would continue 5ASA in 
an out-patient starting oral CS. However, only 140/340 
(41%) would proactively start 5ASA in a hospitalized 
patient not receiving 5ASA before admission. Most 
(94%) physicians consider the safety profile of 5ASA as 
very good. Only 52% consider them inexpensive, 35% 
perceive them to be expensive and 12% are undecided. 
On multi-variable analysis, less years of practice and 
perception of a plausible additive mechanistic effect of 
5ASA + CS were positively associated with the decision 
to continue 5ASA with CS. 
CONCLUSION
Despite the absence of data supporting its benefit, 
most gastroenterologists endorse combination of 5ASA 
+ CS for patients with active moderate-to-severe UC. 
Randomized controlled trials are needed to assess if 
5ASA confer any benefit for these patients.  
Key words: Inflammatory bowel disease; Corticosteroids; 
5-aminosalicylates; Ulcerative colitis
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Patients with moderate-severe active ulce-
rative colitis are often treated with corticosteroids. 
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when combined with corticosteroids for these patients 
has not been explored. This global survey among 
expert gastroenterology physicians in 12 countries 
shows division of opinion regarding this treatment 
choice, but demonstrates that the majority of doctors 
administer corticosteroids with continued 5ASA, despite 
the absence of evidence supporting this combination. If 
this “crowd wisdom” is correct and the addition of 5ASA 
offers even small added benefit for these severely sick 
patients, this could comprise an important simple tool 
for improving outcomes in acute ulcerative colitis. The 
results of this survey call for the need for a controlled 
clinical trial to examine this treatment choice. 
Ben­Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz 
F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, 
Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har­
Noy O, Bernstein CN. Combination of corticosteroids and 
5­aminosalicylates or corticosteroids alone for patients with 
moderate­severe active ulcerative colitis: A global survey of 
physicians’ practice. World J Gastroenterol 2017; 23(16): 
2995­3002  Available from: URL: http://www.wjgnet.
com/1007­9327/full/v23/i16/2995.htm  DOI: http://dx.doi.
org/10.3748/wjg.v23.i16.2995
INTRODUCTION 
The role of corticosteroids (CS) in the treatment of 
moderate-to-severe exacerbation of ulcerative colitis 
(UC) is well established[1-3]. Many of these patients 
present on existing therapy with 5-aminosalycilates 
(5ASA), which are efficacious in mild-moderate UC. 
However, there are no data investigating whether the 
continuation of 5ASA agents in combination with CS 
in patients with a moderate-to-severe UC flare offers 
any additional benefit compared to treatment with CS 
alone. Arguably, 5ASA might act in concert with CS to 
exert an additional therapeutic benefit. Conversely, if 
5ASA are of no benefit in this situation, then patients 
can be spared from an unnecessary drug and its 
unjustified expense. 
Therefore, the goal of the present study was to 
explore the real-life practice of gastrointestinal (GI) 
and inflammatory bowel disease (IBD) experts with 
respect to prescribing 5ASA to patients with moderate-
severe UC needing CS treatment. A secondary aim 
was to investigate factors associated with physicians’ 
therapeutic choices. 
MATERIALS AND METHODS
Design and participants
This was a cross-sectional survey of GI physicians 
in 12 countries in five continents: Australia, Brazil, 
Canada, China, France, Greece, Israel, Italy, Korea, 
Serbia, United Kingdom and United States. GI 
fellows were excluded, but GI specialists were eligible 
regardless of whether they work in a hospital or ex-
clusively at an out-patient setting. The questionnaire 
was distributed by sub-investigators to respondents 
directly or through an additional contact (one-stage 
“Snow-balling” technique). We deliberately elected to 
distribute questionnaires directly, as this technique was 
previously found to result in a higher response rate[4], 
as opposed to low response rates often experienced by 
surveys conducted through mailing lists of professional 
societies’ members or through survey websites[5,6]. 
The study was approved by the Sheba Medical Center 
Institutional Review Board.
Development of questionnaire 
A prior search of the literature did not identify an 
existing questionnaire exploring the research question. 
Therefore, an English-language questionnaire was 
constructed, using a balanced positive and negative-
phrased question structure (Reverse phrasing) to 
reduce response-bias (supplementary Table 1). A 
standardized Likert scale ranging between1-5 was 
used to assess the different degrees of agreement 
to a presented therapeutic strategy. Data about the 
respondent physicians’ professional background were 
also obtained. The questionnaire was approved by 
all co-investigators and was additionally examined 
by three external IBD experts for content validity, to 
ascertain whether the content of the questionnaire 
was appropriate and relevant to the study purpose. 
The questionnaire was distributed to physicians in 
its English format to avoid variations caused by the 
process of translation/back-translation into several 
different languages. Comprehensibility was validated 
by six GI physicians (two native English speakers 
and four non-native speakers). Further, a question 
inquiring about ease of English comprehensibility was 
inserted, and responses from individual physicians 
who graded comprehensibility of the questionnaire as 
less than “easy” or “very easy” were a-priori excluded. 
Additionally, a pre-planned sensitivity analysis was 
performed including only respondents who practice 
medicine in English speaking countries (United States, 
Canada, United Kingdom and Australia). 
Statistical analysis
Descriptive statistics were used to detail distribution 
of responses among the five possible grades of 
agreement for each question. When comparative 
analyses were performed, scales 1 and 2 (“Strongly 
agree” and “tend to agree”) were grouped together 
as responses endorsing the presented therapeutic 
decision, while a Likert response of 4 (“tend to 
disagree”) and 5 (“strongly disagree”) were grouped 
as not endorsing the proposed therapy decision. 
Responses of 3 (“undecided”) were separately 
analyzed. Sample size was determined by taking into 
account five variables, of which four had multiple 
sub items. For the resulting 15 variables, and using 
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in Figure 2A. 
Similarly, when starting oral CS for a non-hospitalized 
outpatient with a mild-moderate UC flare despite 
optimized 5ASA treatment, the majority (212/340, 62%) 
of physicians would continue 5ASA, whereas 97/340 
(28.5%) physicians would stop 5ASA and administer CS 
mono-therapy (P < 0.001; Figure 2B). In contrast, only 
140/340 of the physicians would start 5ASA concurrently 
with CS in a patient hospitalized with UC flare who was 
not already on 5ASA prior to admission, compared to 
172/340 who opted to treat such patients with CS mono-
therapy (P = 0.07; Figure 2C). 
When inquired about English language com-
prehensibility of the questionnaire, 284/347 (82.7%) 
respondents considered it to be very easy, 55 (15.8%) 
as easy, and seven (2%) as fairly understandable. 
None of the respondents rated the questionnaire 
as difficult or as very difficult to comprehend. As 
specified above, the seven respondents with only 
“fair” understanding of the language were excluded 
from further analysis. Nevertheless, to further validate 
the responses, a sensitivity analysis was performed 
including only the 143/340 physicians practicing in 
English-speaking countries (Australia, Canada, United 
States and United Kingdom). Similar to the results 
in the entire cohort, 64.5% of the English-speaking 
physicians endorsed continuing 5ASA in a hospitalized 
steroid-treated patient with moderate-severe UC, and 
73% would continue 5ASA in an out-patient starting 
CS for nonresponsive mild-moderate UC flare.
Perceptions on cost and safety of 5ASA 
To explore if physicians’ perceived costs or safety 
of 5ASA played any role in the therapeutic choice 
between combination 5ASA + CS or corticosteroid 
alone, respondents were also queried about their 
a subject to item ratio of 1:15, at least 225 subjects 
were needed to reduce the risk of over-fitting the 
logistic regression model[6]. Because of the global 
nature of this survey and absence of data on the total 
world number of GI specialists, power calculation for 
total sample size could not be performed, rendering 
the results exploratory. Comparisons of proportions 
were performed by Z test when single population was 
considered or by Fisher exact test when comparing 
proportions between two populations (e.g., responses 
of IBD experts versus non-experts). In the absence of 
definitive definition of what constitutes an IBD expert 
and in line with previous studies[4], respondents with 
≥ 25% of their patients being IBD patients were 
pragmatically defined as IBD experts.
Multi-variable analysis was performed using 
backward logistic regression for all variables of interest. 
All statistics were performed using MedCalc statistical 
software (Marieke, Denmark). P value of < 0.05 was 
considered significant.
RESULTS
Overall, 664 questionnaires were distributed in 12 
countries in five continents. Of these, 349 completed 
questionnaires were received, yielding a response 
rate of 52.6%. Nine questionnaires were excluded: 
Two were received from GI trainees and seven from 
respondents indicating only fair comprehension of 
the questionnaire (four from Italy, two from China 
and one from the United States). Thus, a total of 340 
returned questionnaires were eligible for analysis. The 
distribution of the country of origin among eligible 
respondents is shown in Figure 1. The background 
professional characteristics of the respondents are 
shown in Table 1. 
Physicians’ attitudes toward combination 5ASA-
corticosteroids
Overall, 221 (65%) of the respondents would strongly 
agree or tend to agree to continue 5ASA in a patient 
hospitalized for intravenous CS treatment due to a 
moderate-severe flare of UC, compared with 108 
(32%) who would stop the 5ASA (P < 0.001), and 11 
(3%) who were undecided. This comparison is shown 
Table 1  Background characteristics of survey respondents
Parameter n  (%)
University hospital 256 (78.8)
Practice setting Regional/district 
hospital
  33 (10.1)
Outpatient clinic   36 (11.1)
Less than 25% 183 (55.3)
IBD in clinic 25% or more 
(IBD expert)
148 (46.7)
Years of practice, median 
(IQR, range)
10.5 (5-20, 0.5-60)
Country of practice Australia 31 (9.1)
Brazil 22 (6.5)
Canada   40 (11.8)
China   38 (11.2)
France   9 (2.6)
Greece   46 (13.5)
Israel 33 (9.7)
Italy 19 (5.8)
South Korea 20 (5.9)
Serbia 10 (2.9)
United Kingdom 19 (5.8)
United States   53 (15.6)
China
United States 
South Korea
Greece
Serbia
France
Canada
Italy
Israel
Brazil
Australia
United Kingdom
6%9%
6%
12% 13%
15%
6%
10%
6%
3% 3%
11%
Figure 1  Distribution of countries of practice among the responding 
physicians.
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Figure 2  Distribution of responses for the three strategy choice questions, 
each denoted by the title above. A: Continue 5ASA in a hospitalized steroid-
treated paitent; B: Continue 5ASA in an out-patient staring oral steroids; C: 
Start de-novo 5ASA in a hospitalized steroid-treated patient. The gray bars 
denote the detailed distribution of by percentage of responses to each of the five 
multiple choice answers. The black bars denote the overall comparison between 
proportion of respondents endorsing the strategy (summed percentage of 
“Strongly agree” and “Tend to agree”) vs the proportion of respondents rejecting 
this strategy (summed percentage of “Tend to disagree” and “Strongly disagree”). 
5ASA: 5-Aminosalycilates.
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Figure 3  Distribution of responses for the three physician's perception 
questions, each denoted by the title above. A: 5ASA have very good safety 
profile; B: 5ASA are generally  not expensive; C: 5ASA may have added 
benefit in combination with corticosteroids. The gray bars denote the detailed 
distribution by percentage of responses to each of the five multiple choice 
answers. The black bars denote the overall comparison between proportion of 
respondents agreeing to a contention (summed percentage of “Strongly agree” 
and “Tend to agree”) vs the proportion of respondents rejecting the contention 
(summed percentage of “Tend to disagree” and “Strongly disagree”). 5ASA: 
5-Aminosalycilates.
A
B
C
A
B
C
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opinion towards these topics. Overall, the vast majority 
(94%) of physicians perceive 5ASA as having very 
good safety profile (Figure 3A). However, opinions 
were more split with respect to whether 5ASA are 
expensive, or not (Figure 3B); yet, there was no 
difference in the preference for combination 5ASA + 
CS versus CS alone between physicians who perceived 
5ASA as non-expensive to those who considered them 
expensive (OR = 1.45, 95%CI: 0.88-2.3, P = 0.14). 
There was a trend for physicians who agreed that 
5ASA drugs have very good safety profile to be more 
likely to prefer combination 5ASA + CS, compared to 
physicians who disagreed to the statement of 5ASA 
safety (OR = 4.2, 95%CI: 1.02-17.1, P = 0.045), 
but this analysis was limited by the small number 
of doctors perceiving 5ASA as not very safe (n = 9, 
3% of the respondents). In contrast, physicians who 
professed a belief that mechanistically 5ASA may 
still exert some biologic effect when combined with 
CS, were significantly more likely to prescribe this 
combination compared to those not believing in this 
additive or synergistic mechanism (OR = 7.3, 95%CI: 
4-13.3, P < 0.001). 
Analysis of factors impacting the choice of combination 
5ASA + CS
Along with perceptions on cost and safety of 5ASA, 
several background professional characteristics of 
respondents were investigated for their correlation 
with the decision to administer combination CS + 
5ASA or CS alone. On uni-variable analysis, there 
was a non-significant trend for IBD experts (n = 183) 
to be less likely to endorse combination 5ASA + CS 
compared to GI doctors who are not IBD experts (n 
= 148, OR = 0.63, 95%CI: 0.39-1.03, P = 0.07). 
GI doctors working in an out-patient clinic setting (n 
= 32) were more likely to recommend combination 
5ASA + CS to hospitalized UC patients compared to 
physicians with hospital based positions (n = 281, 
OR = 3.7, 95%CI: 1.3-11.1, P = 0.01). Physicians 
who recommended combination therapy had been 
practicing as a GI expert for a median of 10 years 
(IQR25-75 5-18) compared to median of 13 years (IQR 
6-21.5) for physicians recommending monotherapy 
with CS alone (P = 0.03). On multi-variable analysis, 
however, perception of a plausible synergistic/additive 
mechanism of action for 5ASA with corticosteroids 
and less years of experience as GI expert were the 
only two variables that had a positive independent 
association with the decision to administer combination 
therapy (Table 2). 
DISCUSSION
This study shows widely divergent practices among GI 
physicians and IBD experts with respect to prescribing 
5ASA in combination with CS versus prescribing 
CS alone for patients with active UC. Nevertheless, 
the majority of experts elected to continue 5ASA in 
this scenario, despite the absence of evidence for a 
benefit of this combination. It is possible that some 
physicians who opt against administering 5ASA to 
acute UC patients are wary of bio-availability of orally 
administered drugs in this situation, but this question 
was not investigated in the present study. Many of the 
physicians professed a belief that a biologic additive 
or synergistic effect of 5ASA and CS is plausible and 
also perceive the safety profile of 5ASA as very good, 
presumably leading them to use concurrent 5ASA 
+ CS. However, this is an unproven combination 
with associated costs, and 5ASA safety has not been 
specifically scrutinized in moderate-severe patients. 
Moreover, 5ASA have not been approved for moderate-
severe active UC by any regulatory agency. Thus, 
evidence to support or refute the benefit of 5ASA 
in combination with CS should be sought to enable 
rational and evidence-based therapeutic decisions 
for these patients. Indirect evidence from studies of 
moderate-severe active UC treated with infliximab has 
not indicated a difference in response rate between 
sub-groups of patients treated or not with concomitant 
5ASA[7]. However, data on concurrent 5ASA treatment 
in clinical trials of CS is sparse and even head-to-head 
comparisons of maximal mesalamine dosing with CS 
are lacking[8]. In retrospective cohorts not addressing 
this question directly, sub-groups of CS-treated patients 
with or without 5ASA fared similarly[9-11]. In an analysis 
of patients with CS-induced remission included in three 
Table 2  Uni-variant and multi-variable analysis of factors for their association with prescribing combination 5-Aminosalycilates + 
corticosteroids to a hospitalized moderate-severe ulcerative colitis patient 
Variable Rate Unadjusted odds ratio for 
prescribing combination 
5ASA + CS
95%CI P  value Adjusted odds ratio for 
prescribing combination 
5ASA + CS
95%CI P  value
Believe 5ASA are very safe 94% 4.20 1.02-17.1 0.045 2.9 0.4-22 0.3
Believe 5ASA are not expensive   53% 1.45   0.88-2.3 0.140 1.3  0.7-2.6 0.4
Believe 5ASA mode-of-action may synergize with CS 60% 7.30      4-13.3 0.001 7.9 3.8-17  < 0.001
IBD expert 55% 0.63 0.39-1.03 0.070 0.6  0.3-1.2   0.14
Work in out-patient clinic setting 11% 3.70   1.3-11.1 0.010 2.7 0.6-12 0.2
Years of practice (odds ratio/yr)  - - - -   0.97  0.94-0.99   0.04
5ASA: 5-Aminosalycilates; CS: Corticosteroids; IBD: Inflammatory bowel disease.
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clinical trials, patients who continued mesalamine after 
CS tapering had higher rates of maintained remission 
compared to patients on placebo maintenance[12]. 
Notwithstanding, this comparison may not be extra-
polated to the dilemma of adding 5ASA to CS during the 
induction of remission treatment phase itself. In the only 
study to date directly addressing this question, there 
was statistically significant benefit in univariable analysis 
for reduced complications and need for salvage therapy 
among the 156 patients treated with combination 5ASA 
+ CS compared to CS alone (n = 63)[13]. However, the 
benefit was not demonstrable on multi-variable analysis, 
raising the possibility of additional confounders playing a 
role in the observed results. In the absence of solid data 
to support or reject the use of 5ASA in combination 
with corticosteroids, controlled prospective data are 
imperative, and one such randomized controlled clinical 
trial has been launched[14]. 
Several limitations of the present study should be 
acknowledged. Respondents were approached directly 
by the sub-investigators, thereby making it impossible 
to definitely exclude a selection bias-by-acquaintance. 
However, post-hoc analyses showed that respondents 
approached by any single investigator still had very 
divergent response pattern (data not shown), arguing 
against a homogenous group of “think-alike” experts. 
Moreover, the present methodology allowed for a high 
response rate of > 50%. In contrast, the alternative 
survey methodology whereby physicians are picked 
from a professional society member list or similar non-
personal method, notoriously yields low response rate 
of 10%-40%[5,6]. Such a low response rate may result 
in a different selection bias, whereby participating 
respondents are a minority of the targeted general 
population and not representative of it. Notably, as 
evidence is lacking, physician opinions as obtained 
here are empiric-based, and does not imply that 
the approach of the majority is necessarily the best 
therapeutic strategy. Another limitation of this concise 
questionnaire is that it did not include some additional 
items that may influence physicians’ choices, such as 
local availability of salvage therapies.
In conclusion, this global survey shows that GI and 
IBD experts have diverse 5ASA prescription practices 
for patients with moderate-severe active UC treated 
with CS. Nonetheless, despite the absence of data, the 
majority of experts endorse the use of combination 
5ASA + CS for these patients. Possible adverse events 
- albeit rare - as well as medication costs should be 
borne in mind when making this decision. Conversely, 
experts who do not add 5ASA may be missing out on 
a relatively safe and possibly effective additive therapy. 
Thus, data from prospective clinical trials are direly 
needed for rational evidence-based decision in this 
common clinical scenario. 
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Background
Patients with moderate-severe active ulcerative colitis are often treated with 
corticosteroids. Whether 5-aminosalycilates (5ASA) offer any benefit when 
combined with corticosteroids for these patients has not been explored. 
Moreover, it is unknown how do physicians treating acute ulcerative colitis (UC) 
patients make this therapy choice. If the addition of 5ASA offers even a small 
added benefit for this severely sick patients and saves a minority of them from 
the need for salvage therapy or urgent surgery, this could comprise an important 
simple tool for improving outcomes of these severely ill patients. Conversely, if 
this combination is no more efficacious then corticosteroids alone, then patients 
can be spared from a futile additional drug with its associated costs. Thus, this 
global survey explored the approach of expert gastroenterology physicians 
in 14 countries to combining 5ASA with corticosteroids to gain preliminary 
insight into real-life practice in this scenario and investigate factors driving this 
management decision. 
Research frontiers
Although patients with moderate-severe UC are commonly treated with 
corticosteroids, roughly a third of them will not respond and require salvage 
therapy with infliximab or with cyclosporine and/or urgent colectomy. With these 
limited therapeutic options, investigations into factors that may increase rate of 
response to mainstay corticosteroid treatment are direly needed. This survey 
aims to map gastrointestinal (GI) experts’ strategy with respect to one such 
possible intervention, namely the addition of 5ASA to corticosteroids. 
Innovations and breakthroughs
This is the first study to assess the practice of GI experts with respect to 5ASA 
usage during acute moderate-severe UC. It shows for the first time that despite 
the absence of evidence supporting this strategy, most physicians administer 
combination 5ASA with corticosteroids rather than corticosteroids alone. It also 
provides novel data about factors driving physicians’ decisions in this scenario, 
specifically showing this decision to be driven by mechanistic considerations 
unrelated to costs and safety of medication. 
Applications
This study highlights an often overlooked clinical dilemma - whether to co-treat 
patients with moderate severe UC with combination 5ASA + corticosteroids or 
administer corticosteroids monotherapy. As such, it provides preliminary data 
and framework on which a controlled clinical trial can be based. It will also likely 
to make physicians more cognizant of this clinical decision, spurring further 
research into this - and other interventions - as possible avenues to increase 
the response rate to conventional non-costly and safe therapies in active UC. 
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